E. Mangan

发表

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial

P. Emery, K. Thangavelu, P. Verschueren, 2020, ACR open rheumatology.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

V. Strand, G. Burmester, L. Gossec, 2018, Arthritis Research & Therapy.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

E. Lee, G. Burmester, N. Graham, 2016, Annals of the rheumatic diseases.

Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses

N. Freemantle, E. Choy, Chieh-I Chen, 2019, RMD Open.

FlbT Couples Flagellum Assembly to Gene Expression in Caulobacter crescentus

J. Gober, B. Ely, J. Malakooti, 1999, Journal of bacteriology.

Spatial and temporal phosphorylation of a transcriptional activator regulates pole-specific gene expression in Caulobacter.

J. Wingrove, J. Gober, E. Mangan, 1993, Genes & development.

Temporal and spatial regulation of fliP, an early flagellar gene of Caulobacter crescentus that is required for motility and normal cell division

J. Wingrove, J. Gober, M. Jarvis, 1995, Journal of bacteriology.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double‐blind, placebo‐controlled EIGHT trial

C. Chapple, F. Haab, E. Mangan, 2014, BJU international.

The Unique Cytoplasmic Domain of Human FcγRIIIA Regulates Receptor-Mediated Function

R. Kimberly, A. Gibson, J. Edberg, 2012, The Journal of Immunology.

FunctionRIIIA Regulates Receptor-Mediated g FcThe Unique Cytoplasmic Domain of Human

R. Kimberly, A. Gibson, J. Edberg, 2022 .

C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific.

D. Bharadwaj, C. Mold, T. D. Du Clos, 2000, The Journal of clinical investigation.

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

N. Graham, A. Wells, A. Paccaly, 2019, Rheumatology and Therapy.

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors

V. Strand, N. Graham, R. Fleischmann, 2017, RMD Open.

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies

M. Genovese, G. Burmester, R. Fleischmann, 2020, Arthritis Research & Therapy.

Paul Caulobacter crescentus Expression in FlbT Couples Flagellum Assembly to Gene

J. Gober, B. Ely, J. Malakooti, 1999 .

A mutation that uncouples flagellum assembly from transcription alters the temporal pattern of flagellar gene expression in Caulobacter crescentus

J. Gober, E. Mangan, M. Bartamian, 1995, Journal of bacteriology.

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes

D. M. van der Heijde, M. Genovese, T. Huizinga, 2018, Rheumatology.

222 Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab

P. Emery, S. Jayawardena, P. Verschueren, 2018 .

AB0252 Benefit of Sarilumab with csDMARDs on Patient Productivity in Work, Household Work and Family, Social, Leisure Activities in TNF-IR RA Patients

V. Strand, P. Mahajan, A. Kivitz, 2016 .

SAT0180 Onset of Action of Sarilumab in Patients with Rheumatoid Arthritis in 2 Phase 3 Studies

G. Burmester, D. Thompson, R. Fleischmann, 2016 .

SAT0058 Consistency of Radiographic Responses with Sarilumab plus Methotrexate across Subpopulations of Patients with Rheumatoid Arthritis in A Phase 3 Study

D. M. van der Heijde, M. Genovese, P. Miranda, 2016 .

AB0251 Early Onset of Benefit by Patient-Reported Outcomes (PROs) with Sarilumab Treatment in RA

M. Kosinski, V. Strand, E. Keystone, 2016 .

Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders

J. Weiss, M. Carlsson, E. Mangan, 2017, The Journal of urology.

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs

N. Freemantle, E. Choy, H. van Hoogstraten, 2019, Advances in Therapy.

Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale

V. Strand, L. Gossec, M. Reaney, 2019, The Journal of Rheumatology.

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

M. Oelke, H. Goldman, D. Russell, 2019, International Urogynecology Journal.